Early buyers will receive 10% customization on this report.
This report studies the global ophthalmology drugs and devices market, with forecast to 2017.
The global ophthalmology market witnessed a dip during the economic downturn in 2008 and 2009; however, it is poised to grow at a stable rate mainly due to an increasing aging population, large pool of patients with eye diseases, changing demographics and geographical trends, and increased focus on combination therapies of drugs.
However, lack of awareness of eye diseases hinders the growth of this market. The drugs market will grow at a slower pace mainly due to the combined effect of loss of patent protection for several drugs and drying pipeline. This market is also considered by formulation types, which include capsules, gels, eye drops, ointment, and eye solutions.
The geographies covered in this study are North America, Europe, Asia-Pacific (APAC) and Rest of the world (RoW). North America is the largest market for ophthalmology drugs and devices, followed by Europe and Asia. North America and Europe is expected to grow at a slower pace, primarily due to the economic slowdown and saturation in these markets. APAC is an unsaturated market, especially China and India, and these regions are expected to drive the growth of the overall ophthalmology market, mainly due to growing awareness of eye diseases and increasing disposable income.
The key players in the ophthalmology drugs market are Alcon (U.S.), Allergan, Inc. (U.S.), Merck and Co., Inc. (U.S.), Pfizer, Inc. (U.S.), Roche Holdings AG (Switzerland), and Santen Pharmaceutical Co., Ltd. (Japan). In the devices market, the prominent players are Abbott Medical Optics (U.S.), Alcon, Inc. (Switzerland), Bausch & Lomb, Inc. (U.S.), Carl Zeiss Meditec (Germany), Essilor International S.A. (France), Johnson & Johnson (U.S.), Nidek Co., Ltd. (Japan), and Topcon Corporation (Japan).
About MarketsandMarkets:
MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
